DE69703617D1 - Verwendung von optisch reines (+) norcisapride zur behandlung von erbrechen und zns-störungen - Google Patents

Verwendung von optisch reines (+) norcisapride zur behandlung von erbrechen und zns-störungen

Info

Publication number
DE69703617D1
DE69703617D1 DE69703617T DE69703617T DE69703617D1 DE 69703617 D1 DE69703617 D1 DE 69703617D1 DE 69703617 T DE69703617 T DE 69703617T DE 69703617 T DE69703617 T DE 69703617T DE 69703617 D1 DE69703617 D1 DE 69703617D1
Authority
DE
Germany
Prior art keywords
norcisapride
optically pure
cns disorders
isomer
found
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69703617T
Other languages
English (en)
Other versions
DE69703617T2 (de
Inventor
R Mccullough
P Jerussi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of DE69703617D1 publication Critical patent/DE69703617D1/de
Publication of DE69703617T2 publication Critical patent/DE69703617T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69703617T 1996-07-19 1997-07-02 Verwendung von optisch reines (+) norcisapride zur behandlung von erbrechen und zns-störungen Expired - Fee Related DE69703617T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/684,753 US5739151A (en) 1996-07-19 1996-07-19 Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
PCT/US1997/011629 WO1998003173A1 (en) 1996-07-19 1997-07-02 Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Publications (2)

Publication Number Publication Date
DE69703617D1 true DE69703617D1 (de) 2001-01-04
DE69703617T2 DE69703617T2 (de) 2001-04-12

Family

ID=24749413

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69703617T Expired - Fee Related DE69703617T2 (de) 1996-07-19 1997-07-02 Verwendung von optisch reines (+) norcisapride zur behandlung von erbrechen und zns-störungen

Country Status (25)

Country Link
US (3) US5739151A (de)
EP (1) EP0896539B1 (de)
JP (1) JP3097697B2 (de)
KR (4) KR100399808B1 (de)
CN (1) CN1215992A (de)
AT (1) ATE197762T1 (de)
AU (1) AU3592097A (de)
BG (1) BG63190B1 (de)
BR (1) BR9708287A (de)
CA (1) CA2245768C (de)
CZ (1) CZ293478B6 (de)
DE (1) DE69703617T2 (de)
DK (1) DK0896539T3 (de)
ES (1) ES2152687T3 (de)
GR (1) GR3035460T3 (de)
HU (1) HUP9904360A3 (de)
IL (1) IL125703A0 (de)
IS (1) IS4820A (de)
NO (2) NO317178B1 (de)
NZ (1) NZ331291A (de)
PL (1) PL189610B1 (de)
PT (1) PT896539E (de)
SK (1) SK282673B6 (de)
TR (1) TR199801816T2 (de)
WO (1) WO1998003173A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
CA2263692C (en) * 1996-10-15 2004-06-22 Janssen Pharmaceutica N.V. Synthesis of cisapride
EP1000029B1 (de) * 1997-07-11 2003-10-01 Janssen Pharmaceutica N.V. (+)-norcisapride verwendbar bei 5-ht3 und 5-ht4 bedingten krankheiten
EP1464333A3 (de) * 1998-06-15 2004-12-15 Sepracor Inc. Verwendung von optisch reines (-) Norcisapride in der Behandlung von Apnea, Bulimia und andere Krankheiten
EP1468685A3 (de) * 1998-06-15 2004-12-15 Sepracor Inc. Verwendung von optisch reines (+)-Norcisapride für die Behandlung von Apnea, Bulimia und andere Krankheiten
NZ535055A (en) * 1998-06-15 2006-04-28 Sepracor Inc Use of optically pure (-) norcisapride in the treatment of apnea, and other disorders
CN1312717A (zh) * 1998-06-15 2001-09-12 塞普拉科有限公司 光学纯度(+)—降西沙必利对治疗呼吸暂停、贪食症和其它疾病的用途
ATE316782T1 (de) * 1998-08-21 2006-02-15 Novartis Pharma Gmbh Neue orale formulierungen für 5-ht4 agonisten oder antagonisten
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
EP1321142A1 (de) * 2001-12-21 2003-06-25 Novartis AG Feste orale Zubereitung mit Tegaserod
FR2854072B1 (fr) * 2003-04-23 2006-08-04 Centre Nat Rech Scient Vecteur pour administration par voie orale
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
AU2005205531B2 (en) * 2004-01-07 2011-03-17 Renexxion, Llc Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
WO2006029520A1 (en) * 2004-09-14 2006-03-23 Mcgill University Stimulators of 5-ht4 receptors and uses thereof
EP1919909B1 (de) * 2005-08-31 2013-08-21 Armetheon, Inc. Synthetische verfahren und zwischenprodukte für stereoisomere verbindungen, die sich für die behandlung von erkrankungen des magen-darm-trakts und des zentralen nervensystems eignen
US20080085915A1 (en) * 2006-06-23 2008-04-10 Cyrus Becker Compounds and methods for the treatment of gastrointestinal and central nervous system disorders
KR20120107075A (ko) 2009-10-16 2012-09-28 에파이오메드 테라퓨틱스, 아이엔씨. 구토 치료
RU2587493C2 (ru) * 2011-02-25 2016-06-20 Юхан Корпорэйшн Производные диаминопиримидина и способы их получения

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5114715A (en) * 1990-11-29 1992-05-19 Sepracor Inc. Methods of use and compositions of (s)-isoflurane and (s)-desflurane
US5114714A (en) * 1990-11-29 1992-05-19 Sepracor, Inc. Methods of use and compositions of (r)-isoflurane and (r)-desflurane
AU4770593A (en) * 1992-07-07 1994-01-31 Sepracor, Inc. Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
JPH08502032A (ja) * 1992-07-07 1996-03-05 セプラコア インコーポレーテッド 胃食道逆流疾患およびその他の障害を治療するために▲（−）▼シサプリドを使用する方法
AU7397194A (en) * 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-gastrointestinal motility agent combinations
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Also Published As

Publication number Publication date
ATE197762T1 (de) 2000-12-15
US5739151A (en) 1998-04-14
KR100533237B1 (ko) 2005-12-05
HUP9904360A2 (hu) 2000-05-28
GR3035460T3 (en) 2001-05-31
NZ331291A (en) 2000-06-23
KR100328731B1 (ko) 2002-10-19
EP0896539B1 (de) 2000-11-29
CA2245768C (en) 2003-09-30
IS4820A (is) 1998-08-10
CZ293478B6 (cs) 2004-05-12
SK282673B6 (sk) 2002-11-06
AU3592097A (en) 1998-02-10
CZ250898A3 (cs) 1999-04-14
US6114356A (en) 2000-09-05
KR20000064524A (ko) 2000-11-06
DE69703617T2 (de) 2001-04-12
NO983636L (no) 1998-10-19
BR9708287A (pt) 2000-01-18
DK0896539T3 (da) 2001-02-19
PT896539E (pt) 2001-05-31
US5877188A (en) 1999-03-02
SK123998A3 (en) 1999-03-12
CN1215992A (zh) 1999-05-05
NO983636D0 (no) 1998-08-07
PL189610B1 (pl) 2005-08-31
JPH11510828A (ja) 1999-09-21
KR20040007505A (ko) 2004-01-24
NO20041166L (no) 2004-03-19
HUP9904360A3 (en) 2001-07-30
ES2152687T3 (es) 2001-02-01
JP3097697B2 (ja) 2000-10-10
BG102757A (en) 1999-08-31
PL335254A1 (en) 2000-04-10
TR199801816T2 (xx) 2000-10-23
WO1998003173A1 (en) 1998-01-29
NO317178B1 (no) 2004-09-06
IL125703A0 (en) 1999-04-11
CA2245768A1 (en) 1998-01-29
EP0896539A1 (de) 1999-02-17
BG63190B1 (bg) 2001-06-29
KR100422492B1 (ko) 2004-03-11
KR100399808B1 (ko) 2003-09-29

Similar Documents

Publication Publication Date Title
DE69703617D1 (de) Verwendung von optisch reines (+) norcisapride zur behandlung von erbrechen und zns-störungen
ATE194593T1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
BR9712086A (pt) Inibidores1,4-heterocìclicos de metaloproteinases
ATE229806T1 (de) Wirkstoff zur behandlung neurodegenerativer störungen
IS1904B (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE416164T1 (de) Pharmazeutische zusammenstellungen zur prävention und behandlung von zns-erkrankungen
FI113767B (fi) Bentsimidatsolijohdannaisia, joilla on dopaminergistä vaikutusta keskushermostossa
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet
MA26732A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE69918322D1 (de) Verwendung von optisch reinem (r)-tofizopam zur behandlung und pravention von angststörungen
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
HUP0100611A2 (hu) Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére
BR0012921A (pt) Compostos calcilìticos
PL310950A1 (en) Novel imidazole quinoxalinones, method of obtaining them and their application
DE60039579D1 (de) Humane adulte astrozyten, sowie deren herstellung und verwendung
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE216891T1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
NO990450D0 (no) Behandling av sinnslidelser
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
DE69701258D1 (de) Verwendung von benzonaphtalene-derivaten zur herstellung eines arzneimittels zur behandlung von krankheiten des nervensystems
DK0777663T3 (da) Anvendelse af substituerede 6-amino-4H-pyraner
DE60129846D1 (de) Isochinolin-aroylpyrrole für die behandlung von krankheiten des zentralnervensystems

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee